Valsartan
Approved medicineAlso known as Byvalson, Diovan, Diovan HCT, Entresto+7 more
Byvalson, Diovan, Diovan HCT, Entresto, Exforge, Exforge HCT, N-(P-(O-1H-Tetrazol-5-ylphenyl)benzyl)-N-valeryl-L-valine, Valturna, Hydrochlorothiazide-Valsartan, Sacubitril-Valsartan, Amlodipine/Hydrochlorothiazide/Valsartan.
Recent clinical, regulatory, research and industry developments relating to this drug.
Approval: VALSARTAN (ANDA205357)
Approval: SACUBITRIL AND VALSARTAN (ANDA219946)
Treating Heart Dysfunction Related to Cancer Therapy With Sacubitril/Valsartan (Treat HF)
Glucagon-like Peptide-1 Metabolism in the Setting of Acute Neprilysin Inhibition
Effects of VALsartan On atRIAl Mitral Regurgitation: A Pilot Randomized Controlled Trial
Angiotensin-neprilysin inhibition versus enalapril in heart failure.
Efficacy and safety of valsartan in hypertensive children 6 months to 5 years of age.
Profile
Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.
Pharmacology & targets
Known molecular targets and mechanisms supported by curated pharmacology databases.
Regulatory timeline
The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.
Data from the U.S. Food and Drug Administration (U.S. Food and Drug Administration), public domain (CC0).
Clinical trials
The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.
Late-stage studies
Phase III+ trials still open or recently active — where late-stage evidence is being generated.
Recent completions
Trials that read out recently, adding to the completed evidence base.
Research activity
Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.
Major research themes8
Journals, researchers & institutions
- The New England journal of medicine3
- European journal of heart failure1
- Journal of hypertension1
- Journal of the American Society of Hypertension : JASH1
- Solomon SD4
- McMurray JJ3
- Pfeffer MA3
- Rouleau JL3
- Califf RM2
- Desai AS2
- Leimberger JD2
- Packer M2
- Brigham and Women's Hospital3
- Baylor Heart and Vascular Institute1
- BHF Cardiovascular Research Centre1
- Brigham and Women's Hospital and Harvard Medical School1
- Center for Translational Cardiology and Pragmatic Randomized Trials1
- Centre for Paediatric and Adolescent Medicine1
Related diseases
Regulator-approved indications and conditions co-mentioned with this drug across the research literature. Number shows shared papers.
Related drugs
Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).
Studied across 6 of the same disease areas as Valsartan in the shared literature.
Studied across 6 of the same disease areas as Valsartan in the shared literature.
Studied across the same disease area as Valsartan in the shared literature.
- RxNorm (U.S. National Library of Medicine) — drug identity
- ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
- Europe PMC — research literature
- ClinicalTrials.gov — clinical trials
- Regulatory event sources are credited in the Regulatory Timeline above.